期刊文献+

高脂饮食对阿雷地平及其活性代谢产物人体药动学特征的影响 被引量:3

Effect of high-fat food intake on pharmacokinetics of aranidipine and its active metabolite in healthy Chinese volunteers
原文传递
导出
摘要 目的评价高脂餐对阿雷地平及其活性代谢产物羟基阿雷地平在健康中国人体内药动学的影响。方法10名健康男性受试者空腹口服阿雷地平10 mg,经过1 wk清洗期后,受试者高脂餐后口服阿雷地平10 mg。采用液相色谱-串联质谱联用法测定血浆中阿雷地平及其活性代谢产物羟基阿雷地平的浓度。结果空腹和高脂餐后口服阿雷地平,阿雷地平的c_(max)分别为(2.4±s0.8)和(4.4±2.9)μg·L^(-1),羟基阿雷地平的c_(max)分别为(41±10)和(51±19)μg·L^(-1);空腹和高脂餐后阿雷地平和羟基阿雷地平的c_(max)无显著差异。空腹和高脂餐后口服阿雷地平,阿雷地平的AUC_(0~36)分别为(10.3±2.3)和(15±7)μg·h·L^(-1),羟基阿雷地平的AUC_(0~36)分别为(305±108)和(389±129)μg·h·L^(-1);阿雷地平的t_(max)分别为(4.4±1.0)和(9±6)h,羟基阿雷地平的f_(max)分别为(5.0±1.6)和(11±7)h;空腹和高脂餐后阿雷地平和羟基阿雷地平的AUC_(0~36)和t_(max)均存在显著差异,AUC显著增加,t_(max)显著延长。结论高脂餐后,阿雷地平的吸收出现延迟现象,吸收程度有所增加;羟基阿雷地平的体内生成延迟,但生成的量增加。 AIM To investigate the effects and its active metabolite, hydroxyl-aranidipine, of food intake on the pharmacokinetic profiles of aranidipine in healthy Chinese male volunteers. METHODS Ten male volunteers aged from 18 to 35 were orally administrated with aranidipine tablet 10 mg. After a washout period of a week, volunteers were orally administrated with aranidipine tablet 10 mg after high-fat meal. Plasma concentrations of aranidipine and hydroxyl-aranidipine were determined by HPLC-MS/MS. RESULTS Under fasting and fed conditions, cmax of aranidipine were (2.4 ±s 0.8) and (4.4±2.9) μg·L-1 respectively, cmax of hydroxyl-aranidipine were (41 ± 10) and (51 ±19) μg·L-1, respectively. There was no significant difference in cmax for both aranidipine and hydroxyl-aranidipine. Under fasting and fed conditions, A UC0-36 of aranidipine were (10.3 ±2.3) and (15±7) μg·L-1, AUCo_36ofhydroxyl-aranidipinewere (305 ± 108) and (389 ± 129)μg·L-1. tmax of aranidipine were (4.4 ±1.0) and (9 ± 6) h, tmax of hydroxyl-aranidipine were (5.0 + 1.6) and ( 11 ± 7) h. There was significant increasing in A UC0-36 and tmax for both aranidipine and hydroxyl-aranidipine under fed condition. CONCLUSION Aranidipine shows delay in absorption and increase in absorption level after high-fat meal. The generation of hydroxyl-aranidipine also delays, but the amount of hydroxyl-aranidipine increases.
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2008年第12期890-893,共4页 Chinese Journal of New Drugs and Clinical Remedies
基金 863国家攻关项目“临床试验关键技术及平台研究”(2002AA2Z341A,2004AA2Z3760)。
关键词 阿雷地平 羟基阿雷地平 药动学 色谱法 高压液相 光谱法 质量 电喷雾电离 高脂餐 aranidipine hydroxyl-aranidipine spectrometry, mass, electrospray ionization high-fat pharmacokinetics chromatography, high pressure liquid meal
  • 相关文献

参考文献7

  • 1KANDLA A, HAERUNO A, MIYAJWE H, et al. Antihypertensive of effect of MPC-1304, a novel calcium antagonist, in experimental hypertensive rats and dogs [J]. Cardiovasc Pharmacol, 1992, 20(5): 723-730.
  • 2MITOSHI K, MIYAKE H, ICHILARA K, et al. Contribution of aranidipine metabolites with slow binding kinetics to the vasodilating activity of aranidipine [J]. Naunyn Schmiedebergs Arch Pharmacol, 1997, 355 (1) : 119-125.
  • 3OHASHI K, EBIHARA A. Aranidipine (MPC-1304), a new dihydropyridine calcium antagonist: a review of its antihypertensive action [J]. Cardiovasc Drug Rev, 1996, 14( 1 ) : 1-16.
  • 4U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry Food-Effect Bioavailability and Fed Bioequivalence Studies[EB/OL]. [2007-12-20]. http:// www.fda.gov/cder/guidance/index.htm
  • 5TIAN L, JIANG JJ, HUANG YL, et al. Determination of aranidipine and its active metabolite in human plasma by liquid chromatography/negative electrospray ionization tandem mass spectrometry [J]. Rapid Commun Mass Spectrom, 2006, 20 (19) : 2871-2877.
  • 6MITHANSI SD, BAKAETATSELOU V, TENHOOR CN, et al. Estimation of the increase in solubility of drags as a function of bile salt concentration [J]. Pharm Res, 1996, 13(1): 163-167.
  • 7DRESSMAN JB, AMIDON GL, REPPAS C, et al. Dissolution testing as a prognostic tool for oral drug absorption:immediate release dosage form [J]. Pharm Res, 1998, 15 (1) : 11-22.

同被引文献21

  • 1MASUMIYA H, TANAKA Y, TANAKA H, et al. Inhibition of T-type and L-type Ca(2 + ) currents by aranidipine, a novel di- hydropyridine Ca (2 + ) antagonist [ J ]. Pharmacology, 2000, 61(2) : 57-61.
  • 2OHNO S, KOMATSU O, MIZUKOSHI K, et al. Synthesis of asymmetric 4-aryl-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicar- boxylates with vasodilating and antihypertensive activities [ J ]. Chem Pharm Bull, 1986, 34(4) : 1589-1606.
  • 3KANADA A, HARUNO A, MIYAKE H, et al. Antihypertensive effects of MPC-1304, a novel calcium antagonist, in experimental hypertensive rats and dogs[ J]. J Cardiovasc Pharmacol, 1992, 20(5) : 723-730.
  • 4MIYOSHI K, KANADA A, MIYAKE H, et al. MPC-1304, an- other type of dihydropyridine, possessing highly potent vasodilat- ing action[J]. Eur J Pharmacol, 1993, 238 (2-3) : 139-148.
  • 5OKUMURA K, ICHIHARA K, NAGASAKA M, et al. Calcium entry blocking activities of MPC-1304 and of its enantiomers and metabolites[ J]. Eur J Pharmacol, 1993, 235 ( 1 ) : 69-74.
  • 6OHASHI K, EBIHARA A. Aranidipine( MPC-1304 ), a new di- hydropyridine calcium antagonist: a review of its antihypertensive action[J]. Cardiovasc Drug Rev, 1996, 14(1) : 1-16.
  • 7JIANG J J, TIAN L, HUANG Y L, et al. Pharmacokinetic and Pharmacodynamic characteristics of aranidipine sustained-Re- lease, enteric-coated tablets in healthy Chinese men: a phase I, randomized, open-label, single-and multiple-dose study [ J ]. Clin Ther, 2008, 30(7) : 1290-1313.
  • 8U.S. Department of Health and Human Services, Food and Drug Administration( FDA), Center for Drug Evaluation and Research (CDER). Guidance for industry food-effect bioavallability and fed bioequivalence studies [ EB/OL]. [ 2007-12-20 ]. http: // www. fda. gov/cder/guidance/index. htm.
  • 9CHARMAN W N, PORTER C J, MITHANI S, et al. Physico- chemical and physiological mechanisms for the effects of food on drug absorption: the role of hpids and pH [ J ]. J Pharm Sci, 1997, 86(3) : 182-269.
  • 10MITHANI S D, BAKATSELOU V, TENHOOR C N, et al. Esti- mation of the increase in solubility of drugs as a function of bile salt concentration[J]. Pharm Res, 1996, 13(1): 163-167.

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部